COCH
Envoy Medical, Inc.
There isn't enough reported data to score COCH yet.
COCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Strong |
COCH's balance sheet is currently strong, and its revenue is stable, but its profitability is weak. There isn't enough data to rate its cash flow.
COCH PE Valuation
COCH has no meaningful PE right now: it lost money over the past year.
COCH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect COCH's losses to shrink, with revenue growing.
COCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | +$10.20 |
| Q2 2026 | -$7.70 | +$7.40 |
| Q1 2026 | -$10.20 | +$4.40 |
| Q4 2025 | -$12.30 | +$2.60 |
COCH is still losing money, but far less than before: $4.70 per share over the past year, against $15.10 at its worst in mid-2025.
COCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $66K | +57% |
| Q2 2026 | $51K | -35% |
| Q1 2026 | $39K | -15% |
| Q4 2025 | $75K | +79% |
| Q3 2025 | $42K | -25% |
| Q2 2025 | $78K | +15% |
| Q1 2025 | $46K | -22% |
| Q4 2024 | $42K | -56% |
COCH's revenue is recovering but still below its 2023 peak: $66,000 last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8389% | +5201 points |
| Q2 2026 | -10920% | -4420 points |
| Q1 2026 | -15279% | -4177 points |
| Q4 2025 | -8513% | +2258 points |
| Q3 2025 | -13590% | -4708 points |
| Q2 2025 | -6500% | +647 points |
| Q1 2025 | -11102% | -2801 points |
| Q4 2024 | -10771% | -3682 points |
COCH's operating margin was −8389% last quarter, up 5201 points from the same quarter a year ago.
COCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.1M | -$726K |
| Q4 2025 | -$5.9M | -$2M |
| Q3 2025 | -$4.3M | -$367K |
| Q4 2024 | -$3.9M | +$7.9M |
COCH has burned cash in almost every quarter: −$20M over the past year, against −$23M the year before.
COCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +30.6K shares |
| 1 year | +378% | +8.2M shares |
| 3 years | +96% | +5.1M shares |
COCH has 10M diluted shares, up 378% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
COCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -0.0x | Net Cash |
| Q3 2021 | -0.1x | Net Cash |
COCH has more cash than debt.
COCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 62.7 | Neutral |
COCH's weekly RSI is 49 (neutral) and its Stochastic is 63 (neutral).
COCH PE vs Healthcare Sector
| Metric | COCH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
COCH has no meaningful PE right now: it lost money over the past year.
COCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.72 | 1.3% above |
| 20 week MA | $6.96 | 2.2% below |
| 50 week MA | $6.90 | 1.3% below |
| 100 week MA | $10.1 | 33% below |
| 200 week MA | $32.4 | 79% below |
COCH has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
COCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $97.5 | $97.4 | -0.1% |
| 2022 | $97.4 | $99.7 | +2.4% |
| 2023 | $99.7 | $18.1 | -82% |
| 2024 | $18.1 | $16.0 | -12% |
| 2025 | $16.0 | $7.30 | -54% |
| 2026 YTD | $7.30 | $6.81 | -6.7% |
COCH has finished three years in a row lower, and it's down 6.7% so far in 2026.